Sean Arora, MD

Medical Director, Weight Loss Medicine

Specialties: Obesity Medicine · Telemedicine · Weight Management

About Sean

Dr. Sean Arora is a licensed provider who leads the clinical team at the Arora Health 50-state telemedicine network, the provider group that delivers clinical oversight for Trimi Health. Dr. Arora and the Arora Health providers review patient eligibility for compounded GLP-1 weight management therapy, evaluating each new patient's medical history, BMI, and weight-related comorbidities (type 2 diabetes, hypertension, sleep apnea, dyslipidemia, cardiovascular disease) against FDA labeling thresholds and obesity-medicine clinical guidelines. The clinical focus spans obesity medicine, telemedicine-based chronic care, and metabolic health, working within Trimi's evidence-based protocols, which align with the Endocrine Society's 2024 Obesity Pharmacotherapy Guideline and the AACE Comprehensive Type 2 Diabetes Algorithm 2024. Clinical review covers contraindications such as personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, and severe gastrointestinal disease, and confirms that prescriptions are dispensed only by Trimi's named 503A community sterile compounding pharmacies (VialsRx, Texas State Board pharmacy license #35264, and GreenwichRx). Patient education emphasizes common GLP-1 adverse effects (nausea, vomiting, gallbladder events, acute kidney injury risk if severe GI side effects cause dehydration) and the importance of dose titration to maximize tolerability. Trimi's compounded medications are prepared per individual prescription and are not FDA-approved as drugs; the active ingredients (semaglutide, tirzepatide) are FDA-approved in the corresponding brand formulations (Wegovy/Ozempic and Mounjaro/Zepbound).

Experience

Active board-certified clinician

Board Certifications

Active medical license

Licensed in 1 state

Questions about Sean's role at Trimi

What patients commonly ask about clinician review at Trimi Health.

Who is Dr. Sean Arora?

Dr. Sean Arora is a licensed provider who leads clinical review for compounded GLP-1 weight management therapy at Trimi Health. He practices through the Arora Health 50-state telemedicine network, where each new patient's medical history, BMI, and weight-related comorbidities are evaluated before any compounded prescription is issued.

What does Dr. Arora review when a patient submits an intake?

He reviews the patient's full medical history, current medications, prior weight-loss interventions, BMI calculation, and weight-related comorbidities (type 2 diabetes, hypertension, sleep apnea, dyslipidemia, cardiovascular disease). He confirms eligibility against FDA labeling thresholds (BMI ≥30, or BMI ≥27 with a weight-related comorbidity) and obesity-medicine clinical guidelines, then screens for contraindications.

What contraindications does Dr. Arora screen for?

Personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia type 2 (MEN 2) syndrome, history of pancreatitis, severe gastrointestinal disease, severe renal impairment, current pregnancy or breastfeeding, and any prior serious hypersensitivity reaction to GLP-1 receptor agonists. These contraindications align with FDA prescribing information for semaglutide and tirzepatide.

How does Arora Health work with Trimi?

Arora Health is Trimi's clinical infrastructure partner, a 50-state medical service organization (MSO) and 50-state telemedicine provider network. Dr. Arora is one of the licensed providers in Arora's clinician network who handles patient reviews on Trimi's platform. Arora maintains state-by-state provider licensing and credentialing so Trimi can offer care nationwide.

Who actually prescribes the medication?

A licensed US provider within the Arora Health clinician network, Dr. Arora or another credentialed prescriber, writes the prescription after reviewing the intake. Compounded medications are then dispensed by Trimi's 503A community sterile compounding pharmacy partners: VialsRx (Texas State Board pharmacy license #35264) and GreenwichRx.

Are Trimi's compounded medications FDA-approved?

Trimi's compounded preparations are prepared per individual prescription by 503A community sterile compounding pharmacies and are not themselves FDA-approved as drugs. The active ingredients, semaglutide and tirzepatide, are FDA-approved in the corresponding brand-name finished products (Wegovy/Ozempic and Mounjaro/Zepbound respectively). Compounded versions are prepared from FDA-listed active pharmaceutical ingredients.

What states is Dr. Arora licensed in?

Dr. Arora's individual licensure is listed in the Licensed States card on this page. Through the broader Arora Health network, Trimi has access to licensed prescribers in all 50 US states, if Dr. Arora is not the assigned reviewer for your state, another credentialed Arora provider handles your intake under the same clinical protocols.

What clinical guidelines does Dr. Arora follow?

His review aligns with the Endocrine Society's 2024 Obesity Pharmacotherapy Guideline, the AACE Comprehensive Type 2 Diabetes Algorithm 2024, and FDA prescribing information for the relevant active ingredients. He emphasizes patient education on common GLP-1 adverse effects (nausea, vomiting, gallbladder events, acute kidney injury risk from dehydration) and the importance of dose titration for tolerability.

Treatment information reviewed under this clinical network

Programs and clinical guides for which Sean and other clinicians in the Arora Health network review eligibility.

Get matched with a board-certified provider

Provider review within 24 hours. Compounded semaglutide from $99/month, tirzepatide from $125/month.